126x Filetype PDF File size 2.23 MB Source: www.sahta.com
January 2015 Volume 38, Supplement 1 Standards of Medical Care in Diabetes—2015 S1 Introduction S49 8. Cardiovascular Disease and Risk Management S3 Professional Practice Committee Hypertension/Blood Pressure Control S4 Standards of Medical Care in Diabetes—2015: Dyslipidemia/Lipid Management Summary of Revisions Antiplatelet Agents Coronary Heart Disease S5 1. Strategies for Improving Care S58 9. Microvascular Complications and Foot Care Diabetes Care Concepts Nephropathy Care Delivery Systems Retinopathy When Treatment Goals Are Not Met Neuropathy S8 2. Classification and Diagnosis of Diabetes Foot Care Classification S67 10. Older Adults Diagnostic Tests for Diabetes Treatment Goals Categories of Increased Risk for Diabetes Hypoglycemia (Prediabetes) Pharmacological Therapy Type 1 Diabetes Type 2 Diabetes S70 11. Children and Adolescents Gestational Diabetes Mellitus Monogenic Diabetes Syndromes Type 1 Diabetes Cystic Fibrosis–Related Diabetes Type 2 Diabetes S17 3. Initial Evaluation and Diabetes Management Psychosocial Issues Planning S77 12. Management of Diabetes in Pregnancy Medical Evaluation Diabetes in Pregnancy Management Plan Preconception Counseling Common Comorbid Conditions Glycemic Targets in Pregnancy S20 4. Foundations of Care: Education, Nutrition, Pregnancy and Antihypertensive Drugs Physical Activity, Smoking Cessation, Management of Gestational Diabetes Mellitus Psychosocial Care, and Immunization Management of Pregestational Type 1 Diabetes and Type 2 Diabetes in Pregnancy Diabetes Self-management Education and Support Postpartum Care Medical Nutrition Therapy Physical Activity S80 13. Diabetes Care in the Hospital, Nursing Home, Smoking Cessation and Skilled Nursing Facility Psychosocial Assessment and Care Hyperglycemia in the Hospital Immunization Glycemic Targets in Hospitalized Patients S31 5. Prevention or Delay of Type 2 Diabetes Antihyperglycemic Agents in Hospitalized Patients Lifestyle Modifications Preventing Hypoglycemia Pharmacological Interventions Diabetes Care Providers in the Hospital Diabetes Self-management Education and Support Self-management in the Hospital Medical Nutrition Therapy in the Hospital S33 6. Glycemic Targets Bedside Blood Glucose Monitoring Discharge Planning Assessment of Glycemic Control Diabetes Self-management Education A1C Goals Hypoglycemia S86 14. Diabetes Advocacy Intercurrent Illness Advocacy Position Statements S41 7. Approaches to Glycemic Treatment S88 Professional Practice Committee for the Standards Pharmacological Therapy for Type 1 Diabetes of Medical Care in Diabetes—2015 Pharmacological Therapy for Type 2 Diabetes Bariatric Surgery S90 Index This issue is freely accessible online at care.diabetesjournals.org. Keep up with the latest information for Diabetes Care and other ADA titles via Facebook (/ADAJournals) and Twitter (@ADA_Journals). Diabetes Care Volume 38, Supplement 1, January 2015 S1 I NTR OD UCT I ON Introduction Diabetes Care 2015;38(Suppl. 1):S1–S2 | DOI: 10.2337/dc15-S001 Diabetesisacomplex,chronicillnessre- ADASTANDARDS, STATEMENTS, ADAScientific Statement quiring continuous medical care with ANDREPORTS A scientific statement is an official multifactorial risk-reduction strategies The ADA has been actively involved in ADApoint of view or belief that may or beyond glycemic control. Ongoing pa- the development and dissemination of maynotcontainclinical or research rec- tient self-management education and diabetescarestandards,guidelines, and ommendations. Scientificstatements support are critical to preventing acute related documents for over 20 years. contain scholarly synopsis of a topic re- complications and reducing the risk of ADA’s clinical practice recommenda- lated to diabetes. Workgroup reports long-term complications. Significant tions are viewed as important resources fall into this category. Scientific state- evidence exists that supports a range for health care professionals who care ments are published in the ADA journals of interventions to improve diabetes for people with diabetes. ADA’s “Stan- andother scientific/medical publications, outcomes. dards of Medical Care in Diabetes,” as appropriate. Scientific statements also The American Diabetes Association’s position statements, and scientific undergo a formal review process. (ADA’s) “Standards of Medical Care in statements undergo a formal review Diabetes” is intended to provide cli- process by ADA’s Professional Practice Consensus Report nicians, patients, researchers, payers, Committee (PPC) and the Executive A consensus report contains a compre- and other interested individuals with Committee of the Board of Directors. hensive examination by an expert panel the components of diabetes care, gen- The Standards and all ADA position state- (i.e., consensus panel) of a scientificor eral treatment goals, and tools to eval- ments,scientificstatements,andconsensus medicalissuerelatedtodiabetes.Acon- uate the quality of care. The Standards reports are available on the Association’s sensusreportisnotanADApositionand of Care recommendations are not in- Website at http://professional.diabetes.org/ represents expert opinion only. The cat- tended to preclude clinical judgment adastatements. egory may also include task force and and must be applied in the context of expert committee reports. The need excellent clinical care, with adjustments “Standards of Medical Care in Diabetes” for a consensusreportariseswhenclini- for individual preferences, comorbid- Standards of Care: ADA position state- cians or scientists desire guidance on ities, and other patient factors. For ment that provides key clinical practice a subject for which the evidence is con- more detailed information about man- recommendations.ThePPCperformsan tradictory or incomplete. A consensus agement of diabetes, please refer to extensive literature search and updates report is typically developed immedi- Medical ManagementofType1Diabetes the Standards annually based on the ately following a consensus conference (1) and Medical Management of Type 2 quality of new evidence. where the controversial issue is exten- Diabetes (2). sively discussed. The report represents The recommendations include screen- ADAPosition Statement the panel’s collective analysis, evalua- ing, diagnostic, and therapeutic actions A position statement is an official ADA tion, and opinion at that point in time that are known or believed to favor- pointofvieworbeliefthatcontainsclinical based in part on the conference pro- ablyaffecthealthoutcomesofpatients or research recommendations. Position ceedings. A consensus report does not with diabetes. Many of these interven- statementsareissuedonscientificormed- undergo a formal ADA review process. tionshavealsobeenshowntobecost- ical issues related to diabetes. They are effective (3). publishedinADAjournalsandotherscien- GRADINGOFSCIENTIFICEVIDENCE TheADAstrivestoimproveandupdate tific/medical publications. ADA position Since the ADA first began publishing theStandardsofCaretoensurethatclini- statements are typically based on a sys- practice guidelines, there has been con- cians, health plans, and policy makers can tematic review or other review of pub- siderable evolution in the evaluation of continue to rely on them as the most au- lished literature. Position statements scientific evidence and in the develop- thoritative and current guidelines for di- undergo a formal review process. They ment of evidence-based guidelines. abetes care. are updated annually or as needed. In 2002, we developed a classification “Standards of Medical Care in Diabetes” was originally approved in 1988. Most recent review/revision: October 2014. ©2015bytheAmericanDiabetesAssociation.Readersmayusethisarticleaslongastheworkisproperlycited,theuseiseducationalandnotforprofit, and the work is not altered. S2 Introduction Diabetes Care Volume 38, Supplement 1, January 2015 Table1—ADAevidence-gradingsystemfor“StandardsofMedicalCareinDiabetes” recommendationshavethebestchance Level of of improving outcomeswhenappliedto evidence Description thepopulationtowhichtheyareappro- A Clear evidence from well-conducted, generalizable randomized controlled priate. Recommendations with lower trials that are adequately powered, including levelsofevidencemaybeequallyimpor- c Evidence from a well-conducted multicenter trial tant but are not as well supported. c Evidence from a meta-analysis that incorporated quality ratings in the Of course, evidence is only one com- analysis ponentofclinicaldecisionmaking.Clini- Compelling nonexperimental evidence; i.e., “all or none” rule developed by cians care for patients, not populations; the Centre for Evidence-Based Medicine at the University of Oxford guidelines must always be interpreted Supportive evidence from well-conducted randomized controlled trials that with the individual patient in mind. are adequately powered, including Individual circumstances, such as co- c Evidence from a well-conducted trial at one or more institutions c Evidence from a meta-analysis that incorporated quality ratings in the morbidandcoexistingdiseases,age,ed- analysis ucation, disability, and, above all, B Supportive evidence from well-conducted cohort studies patients’ values and preferences, must c Evidence from a well-conducted prospective cohort study or registry beconsideredandmayleadtodifferent c Evidence from a well-conducted meta-analysis of cohort studies treatment targets and strategies. Also, Supportive evidence from a well-conducted case-control study conventional evidence hierarchies, such C Supportive evidence from poorly controlled or uncontrolled studies as the one adapted by the ADA, may c Evidence from randomized clinical trials with one or more major or three miss nuances important in diabetes or more minor methodological flaws that could invalidate the results care. For example, although there is ex- c Evidence from observational studies with high potential for bias (such as case series with comparison with historical controls) cellent evidence from clinical trials sup- c Evidence from case series or case reports porting the importance of achieving Conflicting evidence with the weight of evidence supporting the multiple risk factor control, the optimal recommendation waytoachieve this result is less clear. It E Expert consensus or clinical experience is difficult to assess each component of such a complex intervention. system to grade the quality of scienti- and codify the evidence that forms the References ficevidencesupportingADArecommen- basis for the recommendations. 1. Kaufman FR (Ed.). Medical Management of dations for all new and revised ADA ADA recommendations are assigned Type 1 Diabetes, 6th ed. Alexandria, VA, Amer- position statements. A recent analysis ratings of A, B,orC, depending on the ican Diabetes Association, 2012 of the evidence cited in the Standards qualityofevidence.ExpertopinionEisa 2. Burant CF (Ed.). Medical Management of of Care found steady improvement in separatecategoryforrecommendations Type 2 Diabetes, 7th ed. Alexandria, VA, Amer- quality over the past 10 years, with last in which there is no evidence from clin- ican Diabetes Association, 2012 3. Li R, Zhang P, Barker LE, Chowdhury FM, year’sStandardsforthefirsttimehaving ical trials, in which clinical trials may Zhang X. Cost-effectiveness of interventions to the majority of bulleted recommenda- beimpractical, or in which there is con- preventandcontroldiabetesmellitus:asystem- tions supported by A-orB-level evi- flicting evidence. Recommendations atic review. Diabetes Care 2010;33:1872–1894 dence (4). A grading system (Table 1) with an A rating are based on large 4. Grant RW, Kirkman MS. Trends in the evi- dence level for the American Diabetes Associa- developed by ADA and modeled after well-designed clinical trials or well- tion’s “Standards of Medical Care in Diabetes” existing methods was used to clarify done meta-analyses. Generally, these from 2005 to 2014. Diabetes Care 2015;38:6–8 P Diabetes Care Volume 38, Supplement 1, January 2015 S3 RO FE SS IO NAL PR A CTI CE CO Professional Practice Committee MMI Diabetes Care 2015;38(Suppl. 1):S3 | DOI: 10.2337/dc15-S002 TT EE The Professional Practice Committee for human studies related to each sec- EdwardW.Gregg,PhD;SilvioE.Inzucchi, (PPC) of the American Diabetes Associa- tionandpublishedsince1January2014. MD; Mark E. Molitch, MD; John M. tion (ADA) is responsible for the “Stan- Recommendations were revised based Morton, MD; Robert E. Ratner, MD; dards of Medical Care in Diabetes” on new evidence or, in some cases, to Linda M. Siminerio, RN, PhD, CDE; and position statement, referred to as the clarify the prior recommendation or Katherine R. Tuttle, MD. “StandardsofCare.”ThePPCisamultidis- match the strength of the wording to ciplinary expert committee comprised of thestrengthoftheevidence.Atablelink- MembersofthePPC physicians, diabetes educators, registered ing the changes in recommendations to dietitians, and others who have expertise newevidencecanbereviewedathttp:// Richard W. Grant, MD, MPH (Chair)* in a range of areas, including adult and professional.diabetes.org/SOC. As for ThomasW.Donner,MD pediatric endocrinology, epidemiology, all position statements, the Standards Judith E. Fradkin, MD publichealth,lipidresearch,hypertension, of Care position statement was reviewed and preconception and pregnancy care. andapprovedbytheExecutiveCommittee Charlotte Hayes, MMSc, MS, RD, CDE, AppointmenttothePPCisbasedonexcel- of ADA’s Board of Directors, which in- ACSMCES lence in clinical practice and/or research. cludeshealthcareprofessionals,scientists, William H. Herman, MD, MPH While the primary role of the PPC is to and lay people. William C. Hsu, MD review and update the Standards of Feedback from the larger clinical Eileen Kim, MD Care, it is also responsible for overseeing community was valuable for the 2015 the review and revisions of ADA’sposition revision of the Standards of Care. Read- Lori Laffel, MD, MPH statements and scientificstatements. ers who wish to comment on the Stan- Rodica Pop-Busui, MD, PhD All members of the PPC are required dards of Medical Care in Diabetesd2015 Neda Rasouli, MD* to disclose potential conflicts of interest are invited to do so at http://professional with industry and/or other relevant or- .diabetes.org/SOC. DesmondSchatz, MD ganizations. These disclosures are dis- The ADA funds development of the Joseph A. Stankaitis, MD, MPH* cussed at the onset of each Standards Standards of Care and all ADA position Tracey H. Taveira, PharmD, CDOE, of Care revision meeting. Members of statements out of its general revenues CVDOE the committee, their employer, and and does not use industry support for their disclosed conflicts of interest are these purposes. Deborah J. Wexler, MD* listed in the “Professional Practice Com- The PPC would like to thank the fol- *Subgroup leaders mittee for the Standards of Medical lowing individuals who provided their ex- Care in Diabetesd2015” table (see pertise in reviewing and/or consulting with ADAStaff p. S88). the committee: Donald R. Coustan, MD; For the current revision, PPC mem- Stephanie Dunbar, MPH, RD; Robert H. Jane L. Chiang, MD bers systematically searched MEDLINE Eckel, MD; Henry N. Ginsberg, MD; Erika Gebel Berg, PhD ©2015bytheAmericanDiabetesAssociation.Readersmayusethisarticleaslongastheworkisproperlycited,theuseiseducationalandnotforprofit, and the work is not altered.
no reviews yet
Please Login to review.